Christine Johnston says biosimilar interchangeability bills, plus 2026 PBM reforms, would force PBMs to justify preferring higher-cost brands. Proposed legislation that would make approved biosimilars ...
Chad Hatfield, Pharm.D., of UC Davis Health, says 340B savings fund free clinics and mental health care that could shrink as the program’s future shifts. The future of the 340B Drug Pricing Program ...
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Ty Gluckman, M.D., says the 2026 dyslipidemia guideline brings back risk-based LDL goals, and clinical inertia, not access, ...
Ty Gluckman, M.D., says undertesting and undertreatment are the biggest gaps in lipid care and calls on leaders to invest in ...
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B ...
The chief pharmacy officer role has changed significantly over the past five years, shifting away from running operations and ...
Robotic lobectomies grew from 49% to 70% of cases from 2020 to 2024 as access and training expanded, says Staci Beamer, M.D., ...
Structure is the first step toward better sleep for children with ADHD, according to Alison Pritchard, Ph.D., a child ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results